Abstract Number: 1371 • 2018 ACR/ARHP Annual Meeting
Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis
Background/Purpose: Current ACR guidelines recommend the use of IACS for short-term acute pain relief in patients (pts) with knee OA.1 Bilateral knee OA can occur…Abstract Number: 1372 • 2018 ACR/ARHP Annual Meeting
An Analysis of the Quality and Readability of Online Osteoarthritis Information with Historical Comparison
Background/Purpose: OA is the most common cause of disability in people >65 years old.Most patients in the USA use the internet for healthcare information. The…Abstract Number: 1373 • 2018 ACR/ARHP Annual Meeting
Predictive Probabilities Are Superior in Communicating the Clinical Relevance of Cartilage Thickness As an Imaging Biomarker of Knee Osteoarthritis Progression
Background/Purpose: Establishing a threshold of clinically important cartilage loss is of great interest for the design and interpretation of knee OA trials of structure-modifying treatments.…Abstract Number: 1374 • 2018 ACR/ARHP Annual Meeting
The Relationship between Loneliness and Osteoarthritis in US Adults from a Nationally Representative Survey
Background/Purpose: Loneliness in adults is a growing phenomenon across the Western world. It is associated with increased mortality, depression, coronary heart disease and stroke. Moreover,…Abstract Number: 1375 • 2018 ACR/ARHP Annual Meeting
Comparative Safety of Flavocoxid (Limbrel) Versus Nsaids Among Osteoarthritis Patients
Background/Purpose: Flavocoxid is a medical food formulated to assist in the management of patients with osteoarthritis (OA). Safety concerns based on case reports have been…Abstract Number: 1376 • 2018 ACR/ARHP Annual Meeting
The Omeract-Oarsi Core Set of Outcome Domains to Measure in Clinical Trials for People with Hip and/or Knee Osteoarthritis
Background/Purpose: It has been over 20 years since the OMERACT core outcome set (COS) to measure in clinical trials with people who have hip and/or…Abstract Number: 1377 • 2018 ACR/ARHP Annual Meeting
Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment
Background/Purpose: Impaired descending pain inhibition has been observed in people with knee OA and may be associated with development of chronic pain as well as…Abstract Number: 1378 • 2018 ACR/ARHP Annual Meeting
Validation of a Spanish Version of the Functional Index for Hand Osteoarthritis (FIHOA)
Background/Purpose: Hand Osteoarthritis (HOA) is a highly prevalent disease with important impact on the patient´s daily activity performance and quality of life. Dreiser et al.…Abstract Number: 1379 • 2018 ACR/ARHP Annual Meeting
Appraisal of the Educational Needs in Patients with Osteoarthritis Using the Educational Needs Assessment Tool Questionnaire
Background/Purpose: The SpENAT, a Spanish version of the Educational Needs Assessment Tool (ENAT), is a self-completed questionnaire that assesses educational needs (ENs) in ostheoathritis (OA)…Abstract Number: 1380 • 2018 ACR/ARHP Annual Meeting
Complications Following Total Hip Arthroplasty in Inflammatory Versus Osteoarthritis
Background/Purpose: THA is commonly performed in patients with a history of inflammatory arthritis. These patients are likely at higher risk of complications, from both the…Abstract Number: 1381 • 2018 ACR/ARHP Annual Meeting
Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement
Background/Purpose: Up to 20% of Total Joint Replacement (TJR) patients are dissatisfied, but this is difficult to study as it is challenging to pool data…Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…Abstract Number: 1383 • 2018 ACR/ARHP Annual Meeting
Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis
Background/Purpose: The FDA encourages clearance of skin findings as a primary outcome of clinical trials for inflammatory skin conditions. However, some DM patients retain signs…Abstract Number: 1384 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
Background/Purpose: Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily the sacroiliac joints and spine and can cause irreversible damage. Measuring disease…Abstract Number: 1385 • 2018 ACR/ARHP Annual Meeting
Subjective Well-Being Among Rheumatoid Arthritis Patients
Background/Purpose: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related…
ACR Meeting Abstracts